Gene therapy for glioblastoma in adult patients: Safety and efficacy evaluation of an in situ injection of recombinant retroviruses producing cells carrying the thymidine kinase gene of the herpes simplex type 1 virus, to be followed with the administration of ganciclovir

Human Gene Therapy

Volumn 7, Issue 1, 1996, Pages 109-126

  Klatzmann, D ^a   Philippon, J ^a   Valery, C A ^a   Bensimon, G ^a   Salzmann, J L ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; RECOMBINANT DNA; THYMIDINE KINASE;

ARTICLE; BLOOD TOXICITY; CELL KILLING; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG SENSITIVITY; FOLLOW UP; GASTROINTESTINAL TOXICITY; GENE EXPRESSION; GENE THERAPY; GLIOBLASTOMA; HEALTH INSURANCE; HERPES SIMPLEX VIRUS 1; HUMAN; INFORMED CONSENT; LABORATORY TEST; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROGNOSIS; RETROVIRUS; SAFETY; SKIN MANIFESTATION; VIRUS RECOMBINANT;

EID: 0029922308     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1996.7.1-109     Document Type: Article

References (0)